Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-05297909
- Development stage
- Phase 1
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
PF-05297909 is an orally administered small molecule drug that was developed by Pfizer for the treatment of Alzheimer's disease. It functions as a beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor and amyloid precursor protein (APP) modulator, targeting the reduction of beta-amyloid production implicated in Alzheimer's pathology. The drug reached phase 1 clinical trials but development was discontinued after completion of these early studies. Its precise mechanism of action remains incompletely defined in public sources, but it is classified among antidementia agents and BACE1 inhibitors.
02
Targets
Aβ (Amyloid-beta peptides and aggregates)BACE1 (Beta-site APP-cleaving enzyme 1)
Beyond the preview
Go deeper on PF-05297909.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-05297909.